Sickle Cell Disease Treatment Market

The sickle cell disease treatment market size is estimated to reach $1.6 billion by 2031, growing at a CAGR of 4.1% from 2022 to 2031.

WILMINGTON, DELAWARE , UNITED STATES, April 8, 2024 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, “Sickle Cell Disease Treatment Market," The sickle cell disease treatment market size was valued at $1.1 billion in 2021, and is estimated to reach $1.6 billion by 2031, growing at a CAGR of 4.1% from 2022 to 2031.

The report conducts a thorough examination of top segments, evolving market trends, value chains, key investment areas, competitive scenarios, and regional landscapes. Serving as a vital and informative resource, it aids leading market players, investors, newcomers, and stakeholders in crafting fresh strategies for the future and implementing measures to fortify their market standing.

The global sickle cell disease treatment market is segmented based on drug type, type, route of administration, and region.

In terms of drug type, the hydroxyurea segment dominated the market in 2021, representing over three-fifths of the market share. Nevertheless, the adakveo segment is expected to witness the highest Compound Annual Growth Rate (CAGR) of 5.9% during the forecast period.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/A31450

Regarding type, the sickle cell anemia segment led the market in 2021, capturing more than half of the market share. Furthermore, this segment is anticipated to demonstrate the highest CAGR of 4.7% from 2022 to 2031.

Based on the route of administration, the oral segment accounted for the largest share in 2021, encompassing approximately four-fifths of the market. However, the parenteral segment is forecasted to exhibit the highest CAGR of 4.3% during the forecast period.

The analysis of the global sickle cell disease treatment market spans across various regions including North America, LAMEA, Asia-Pacific, and Europe. North America dominated the market in 2021, holding approximately two-fifths of the market share. However, the market in Asia-Pacific is projected to witness the highest Compound Annual Growth Rate (CAGR) of 5.7% from 2022 to 2031.

𝑭𝒐𝒓 𝑷𝒖𝒓𝒄𝒉𝒂𝒔𝒆 𝑰𝒏𝒒𝒖𝒊𝒓𝒚- https://www.alliedmarketresearch.com/purchase-enquiry/31900

𝑲𝑬𝒀 𝑭𝑰𝑵𝑫𝑰𝑵𝑮𝑺 𝑶𝑭 𝑻𝑯𝑬 𝑺𝑻𝑼𝑫𝒀
• Based on drug type, the hydroxyurea segment held largest share in the global sickle cell disease treatment industry in 2021.
• On the basis of type, the sickle cell anemia segment held largest market share in 2021, and is expected to continue this trend during the forecast period.
• Based on route of administration, oral segment dominated the market in 2021. However, parenteral segment is expected to grow at a CAGR of 4.3% during the forecast period.
• On the basis of region, North America held largest share in the global market in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR of 5.7% during the forecast period.

𝑲𝒆𝒚 𝑩𝒆𝒏𝒆𝒇𝒊𝒕𝒔 𝑭𝒐𝒓 𝑺𝒕𝒂𝒌𝒆𝒉𝒐𝒍𝒅𝒆𝒓𝒔
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the sickle cell disease treatment market analysis from 2021 to 2031 to identify the prevailing sickle cell disease treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the sickle cell disease treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global sickle cell disease treatment market trends, key players, market segments, application areas, and market growth strategies.

𝑲𝒆𝒚 𝑴𝒂𝒓𝒌𝒆𝒕 𝑷𝒍𝒂𝒚𝒆𝒓𝒔
Agios Pharmaceuticals
Bristol Myers Squibb Company
CRISPR Therapeutics
Editas Medicine
Emmaus Life Sciences, Inc.
Global Blood Therapeutics, Inc.
Medunic USA, Inc.
Novartis AG
Novo Nordisk
Vifor Pharma

The report scrutinizes the key players operating in the global sickle cell disease treatment market. These players have implemented diverse strategies including new product introductions, expansions, partnerships, and other initiatives to enhance their market presence and fortify their standing within the industry. It serves as a valuable resource for evaluating the business performance, operational segments, product portfolio, and advancements of each market player.

David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.